C92.61
Acute myeloid leukemia with 11q23-abnormality in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Acute myeloid leukemia (AML) with 11q23-abnormality is a subtype of blood cancer that affects the myeloid cells in the bone marrow. When diagnosed as being in remission, it indicates that signs of the disease are not currently detectable after treatment. This condition involves genetic mutations, specifically abnormalities in the 11q23 region, which can influence both the disease course and response to therapy. Understanding this condition is crucial for patients and caregivers to comprehend the implications, ongoing management, and prognosis associated with AML in remission.
Causes & Symptoms
Clinical Causes: The exact cause of AML with 11q23-abnormality is not entirely understood. It is believed to result from genetic mutations that occur in blood-forming cells, leading to abnormal growth and accumulation of myeloid cells. Factors that may contribute include: - Exposure to certain chemotherapy agents or radiation therapy - Prior history of other blood disorders - Genetic predispositions - Environmental factors such as benzene exposure While these factors might increase the risk, most cases are diagnosed without a clear external cause. The specific 11q23 abnormality involves rearrangements or translocations in chromosome 11, which play a pivotal role in the development of this cancer subtype.
Key Symptoms: During active phases of AML, symptoms can include: - Fatigue and weakness - Fever and frequent infections - Easy bruising or bleeding - Shortness of breath - Pale skin - Petechiae (small red or purple spots on the skin) - Bone or joint pain When in remission, individuals typically do not exhibit these symptoms, but ongoing monitoring is essential to detect any signs of relapse.
Diagnostic & Treatment
Diagnosis Path: Diagnosing AML with 11q23-abnormality involves several steps: - Blood tests: Complete blood count (CBC) to identify abnormal levels of blood cells - Bone marrow biopsy: To examine the number and appearance of myeloid cells - Cytogenetic analysis: To detect specific genetic abnormalities, including translocations in chromosome 11 - Molecular testing: To identify mutations associated with the 11q23 region These diagnostic procedures help confirm the subtype and assess the disease status, guiding treatment planning and monitoring in remission.
Treatment Protocols: Treatment for AML with 11q23-abnormality typically involves a combination of therapies, which may include: - Chemotherapy: To eradicate remaining leukemia cells - Targeted therapy: Depending on specific genetic features, targeted drugs may be used to inhibit abnormal cell growth - Stem cell transplantation: In certain cases, a bone marrow or stem cell transplant may be considered to attempt a cure, especially for high-risk patients - Supportive care: Including transfusions, antibiotics, and growth factors to manage symptoms and complications While achieving remission indicates disease control, ongoing follow-up is necessary to monitor for potential relapse and manage any side effects of treatment.
Clinical Advice & FAQs
Billing Guidance
Is C92.61 a billable ICD-10 code?
Yes, C92.61 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.61?
Clinical documentation must specify the nature of Acute myeloid leukemia with 11q23-abnormality in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference